About Urovant Sciences
Urovant Sciences is a publicly listed company based in Irvine (United States) founded in 2017. It operates as a therapies for urological disorders such as overactive bladder are developed. Its chief executive is Keith Katkin. Urovant Sciences offers products and services including Drug Pipeline and Cell and Gene Therapies. Its focus areas include Life Sciences, Genitourinary Disorders and Drugs. Its legal entity is Sumitomo Pharma America, Inc. Its competitors include Lipella, TheraVida, Esprit Pharma, Regenfro Co and Kissei Pharmaceutical and 4 more; 8 of its 9 listed competitors have raised funding.
Company details
Urovant Sciences was founded in 2017 and is headquartered in Irvine, United States. The company operates in the biotechnology sector, focusing on the development of therapies for urological disorders. Its lead candidate, vibegron, a beta-3 agonist small molecule, targets conditions including overactive bladder, benign prostatic hyperplasia, and irritable bowel syndrome. Operations emphasize research and clinical advancement of these treatments.
- Headquarters Irvine, United States
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website urovant.com
- Social LinkedIn X
- Legal Name Sumitomo Pharma America, Inc.
- Net Profit-$146.75 M (USD)-32as on Mar 31, 2020
- EBITDA-$146.71 M (USD)-32as on Mar 31, 2020
- Latest Funding Round$100M (USD), Debt – Conventional
Feb 2019
- Investors
Products & Services of Urovant Sciences
Urovant Sciences offers a comprehensive portfolio of products and services, including Drug Pipeline and Cell and Gene Therapies.
Develops innovative treatments for oncology and health areas
Advances therapies for rare diseases and neurology
Funding Insights of Urovant Sciences
- Total Rounds 1
- Last Round Debt – Conventional — $100M
- First Round $100M
(Feb 2019)
- Investors Count 1
All 1 funding rounds of Urovant Sciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2019 | $100M | Debt – Conventional | – | – |
1 investors in total: 1 institutional.
Investors in Urovant Sciences
Urovant Sciences has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Hercules Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt financing is provided to companies in multiple sectors. | 2003 | htgc.com | Palo Alto, United States |
Investor details for Urovant Sciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Urovant Sciences
51 people are tracked at Urovant Sciences (14 in leadership, 4 in board & advisors, 33 in team).
| Name | Role | Group |
|---|---|---|
Keith Katkin | CEO & President | Leadership |
James Robinson | President & CEO | Leadership |
Betzy Estrada | EVP & Chief Human Resources Officer | Leadership |
Alana Darden Powell | VP, Marketing | Leadership |
Laura Genatossio | SVP & General Manager, Europe | Leadership |
Shree Bhutani | Director, Sales Operations | Leadership |
Donny Birjah | Area Vice President Specialty Sales | Leadership |
Katherine S. | Compliance Sr. Director | Leadership |
Teresa Ciborowski | Executive Director Of Human Resources | Leadership |
Eric Jackson | Sr. Director, Managed Markets, Access & Pricing | Leadership |
David Musselman | Vice President, Sales And Commercial Strategy | Leadership |
Achsah Warren | Vice President Compliance | Leadership |
Robert Ryder | Senior Director Commercial Operations | Leadership |
Tom Cunningham | Director Commercial Manufacturing | Leadership |
Myrtle Potter | Chairman | Board & advisors |
James M. Hindman | Board Member | Board & advisors |
Pierre Legault | Board Member | Board & advisors |
Shigeyuki Nishinaka | Board Member | Board & advisors |
Mark Niemaszek | SVP, Corporate Planning | Team |
Travis Hicks | LTC Territory Manager At Urovant Sciences | Team |
31 more people are available in the full profile.
Complete people profiles for Urovant Sciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Urovant Sciences
3 dated milestones of Urovant Sciences across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Urovant Sciences is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $100.0M.
Competitors of Urovant Sciences
Urovant Sciences has 9 listed competitors in our database, 8 of them funded. They include Lipella, TheraVida, Esprit Pharma, Regenfro Co and Kissei Pharmaceutical, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lipella.com | 2005 | Pittsburgh, United States | $3.37M | 5 | Lipid-based therapies for common bladder syndromes are developed. | |
| theravida.com | 2005 | San Mateo, United States | $12.5M | – | Clinical stage biopharma company developing drugs for urology and central nervous system disorders | |
| espritpharma.com | 2005 | East Brunswick, United States | $219.49M | – | Develop drugs for genitourinary (GU) disorders | |
| regenephro.co.jp | 2019 | Kyoto, Japan | $28.88M | – | Developer of therapeutics to treat renal diseases | |
| kissei.co.jp | 1946 | Matsumoto, Japan | – | – | Therapies for renal diseases and urology-related anemia are developed. | |
| aceruspharma.com | 2008 | Mississauga, Canada | $38.07M | – | Develops pharmaceuticals for urology, hormone replacement therapy, and female sexual dysfunction treatments. | |
| ixchelsis.com | 2011 | Sandwich, United Kingdom | $26M | 4 | Develops oxytocin receptor antagonists for treating genitourinary disorders. | |
| urigen.com | 1997 | North Brunswick, United States | $3.02M | – | Pain relief products for urological ailments are developed and tested. | |
| ixaltis.com | 2012 | Toulouse, France | $8.89M | – | Therapeutics for genito-urinary diseases including stress urinary incontinence are developed. |
Detailed competitors of Urovant Sciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genitourinary Disorders
10 companies that operate in the same segment as Urovant Sciences (Genitourinary Disorders), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | – | – | |
Provider of surgical devices for vertical hernia repair and abdominal wall reconstruction | 2012 | Malvern, Pennsylvania, United States | USD 104.6 M | USD 80.28 M | 209 | |
Therapeutics for infectious and autoimmune diseases are developed. | 2010 | Cambridge, Massachusetts, United States | USD 470.49 M | – | 71 | |
Miniaturized injectable neuromodulation devices are developed for chronic diseases. | 2014 | Santa Clara, California, United States | USD 123.59 M | – | – | |
Developer of a therapeutic solution to treat prostate, kidney, and bladder cancer | 2018 | Maple Grove, Minnesota, United States | USD 157 M | – | 29 | |
A device is developed to treat urinary obstruction from BPH. | 2014 | Palo Alto, California, United States | USD 48 M | – | 25 | |
Minimally invasive devices in urology | 2004 | Mountain View, California, United States | USD 137.96 M | – | 119 | |
Diagnostic devices for lower urinary tract diseases are developed. | 2021 | Aliso Viejo, California, United States | USD 94.99 M | – | 23 | |
Medical device for benign prostatic hyperplasia treatment is developed. | 2021 | Milwaukee, Wisconsin, United States | USD 54.16 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Urovant Sciences
Complete news archive for Urovant Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Urovant Sciences
Urovant Sciences was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Urovant Sciences is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
Keith Katkin is the current CEO of Urovant Sciences.
Urovant Sciences was founded in 2017 and is headquartered in Irvine, United States. The company operates in the biotechnology sector, focusing on the development of therapies for urological disorders. Its lead candidate, vibegron, a beta-3 agonist small molecule, targets conditions including overactive bladder, benign prostatic hyperplasia, and irritable bowel syndrome. Operations emphasize research and clinical advancement of these treatments.
Urovant Sciences's top competitors include Lipella, Kissei Pharmaceutical and Regenfro Co.
Urovant Sciences offers Drug Pipeline and Cell and Gene Therapies.
Urovant Sciences has 1 investor. Key investors include Hercules Capital.
Urovant Sciences operates through Sumitomo Pharma America, Inc..